Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.77 USD
-0.24 (-4.79%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $4.90 +0.13 (2.73%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 81 - 100 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
CRL Issued on LPCN 1021 Over Its Dose-Adjustment Protocol
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Q1 Lower on Launch Prep, TLANDO (LPCN 1021) PDUFA June 28
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
1107?s Progesterone Plasma > Makena; PT Up $4 to $40
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Enrollment of LPCN 1111, Potentially First Once-a-day TRT, Is Underway
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Lack of AdCom Reduces LPCN 1021?s Regulatory Risk, as BD Season Begins
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
2Q15 Generally Inline; As Lipocine Starts To Bulk Up.
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Lipocine Inc.
Industry: Medical - Drugs
LPCN Initiation: LPCN 1021, On Track To Become First Oral TRT in $2.5B Market
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M